Literature DB >> 28166196

The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.

J Wakim1, E Arman1, S Becker-Herman2, M P Kramer2, E Bakos2, I Shachar2, A Elson1.   

Abstract

The tyrosine phosphatase PTPROt is a suggested tumor suppressor (TS) in B-cell chronic lymphocytic leukemia (CLL), and its expression is reduced in this disease. In order to examine how reduced PTPROt expression affects CLL in vivo we induced CLL in PTPROt-targeted mice. Unexpectedly, loss of both Ptprot alleles delayed disease detection and progression and lengthened survival relative to mice carrying two intact alleles, indicating that PTPROt fulfills a novel tumor-promoting role in CLL. Tumor cells from mice lacking PTPROt exhibited reduced B-cell receptor (BCR)-induced signaling, as well as increased apoptosis and autophagy. Inhibition of BCR/Src signaling in CLL cells induced their apoptosis, indicating that these findings are linked causally. These results suggest a cell-autonomous mechanism for the weakened CLL phenotype of PTPROt-deficient mice and uncover non-redundant roles for PTPROt in support of BCR signaling and survival of CLL cells. In contrast, loss of only one Ptprot allele induced earlier detection and progression of CLL and reduced survival, consistent with a tumor-suppressing role for PTPROt. Tumor cells from mice lacking one or both Ptprot allele exhibited increased interleukin-10 (IL-10) expression and signaling, factors known to support CLL; cells lacking one Ptprot alleles exhibited normal BCR signaling and cell death rates. We conclude that loss of one Ptprot allele promotes CLL, most likely by activating IL-10 signaling. Loss of both Ptprot alleles also reduces BCR signaling and increases cell death rates, offsetting the IL-10 effects and reducing the severity of the disease. PTPROt thus functions as an obligate haploinsufficient TS in CLL, where its expression levels determine its role as a promoter or inhibitor of the tumorigenic process in mice. Partial loss of PTPROt generates the strongest disease phenotype, suggesting that its intermediate expression levels in CLL are selected for.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28166196     DOI: 10.1038/onc.2016.523

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

1.  Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.

Authors:  Linfeng Chen; Przemyslaw Juszczynski; Kunihiko Takeyama; Ricardo C T Aguiar; Margaret A Shipp
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

2.  PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest.

Authors:  R C Aguiar; Y Yakushijin; S Kharbanda; S Tiwari; G J Freeman; M A Shipp
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

3.  Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

Authors:  Giovanni Galletti; Cristina Scielzo; Federica Barbaglio; Tania Véliz Rodriguez; Michela Riba; Dejan Lazarevic; Davide Cittaro; Giorgia Simonetti; Pamela Ranghetti; Lydia Scarfò; Maurilio Ponzoni; Martina Rocchi; Angelo Corti; Achille Anselmo; Nico van Rooijen; Christian Klein; Carola H Ries; Paolo Ghia; Michele De Palma; Federico Caligaris-Cappio; Maria Teresa Sabrina Bertilaccio
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

4.  Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.

Authors:  Tasneem Motiwala; Jharna Datta; Huban Kutay; Satavisha Roy; Samson T Jacob
Journal:  J Cell Biochem       Date:  2010-07-01       Impact factor: 4.429

Review 5.  The TCL1 family of oncoproteins: co-activators of transformation.

Authors:  Michael A Teitell
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

6.  Subtle variations in Pten dose determine cancer susceptibility.

Authors:  Andrea Alimonti; Arkaitz Carracedo; John G Clohessy; Lloyd C Trotman; Caterina Nardella; Ainara Egia; Leonardo Salmena; Katia Sampieri; William J Haveman; Edi Brogi; Andrea L Richardson; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

7.  An osteoclastic protein-tyrosine phosphatase is a potential positive regulator of the c-Src protein-tyrosine kinase activity: a mediator of osteoclast activity.

Authors:  K-H William Lau; Li-Wha Wu; Matilda H-C Sheng; Mehran Amoui; Sung Min Suhr; David J Baylink
Journal:  J Cell Biochem       Date:  2006-04-01       Impact factor: 4.429

8.  BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

Authors:  Przemyslaw Juszczynski; Linfeng Chen; Evan O'Donnell; Jose M Polo; Stella M Ranuncolo; Riccardo Dalla-Favera; Ari Melnick; Margaret A Shipp
Journal:  Blood       Date:  2009-10-23       Impact factor: 22.113

9.  Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.

Authors:  Giorgia Simonetti; Maria Teresa Sabrina Bertilaccio; Paolo Ghia; Ulf Klein
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

10.  Molecular cloning of cDNAs encoding human GLEPP1, a membrane protein tyrosine phosphatase: characterization of the GLEPP1 protein distribution in human kidney and assignment of the GLEPP1 gene to human chromosome 12p12-p13.

Authors:  R C Wiggins; J E Wiggins; M Goyal; B L Wharram; P E Thomas
Journal:  Genomics       Date:  1995-05-01       Impact factor: 5.736

View more
  2 in total

Review 1.  Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.

Authors:  Mariana Tannús Ruckert; Pamela Viani de Andrade; Verena Silva Santos; Vanessa Silva Silveira
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.207

Review 2.  Regulatory Functions of Protein Tyrosine Phosphatase Receptor Type O in Immune Cells.

Authors:  Feiling Xie; Hongmei Dong; Hao Zhang
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.